ArticleAsia Oceania journal of nuclear medicine & biology2017
Diagnosis of Brain Tumors Using Amino Acid Transport PET Imaging with
Article in Asia Oceania journal of nuclear medicine & biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Clinical Practice Guidelines forAnnals of nuclear medicine · 2025Guideline
- Determining the extent of tumor resection at surgical planning withAnnals of nuclear medicine · 2021Trial
- Metabolic Imaging and Molecular Signatures Reveal Metabolic Phenotypes in Recurrent Glioblastoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Unexpected [18F]-fluciclovine hyperuptake in radiation necrosis after proton therapy: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- CD98 Light Chain LAT1 Tracers in PET-CT Diagnosis of Cancer Patients.Anti-cancer agents in medicinal chemistry · 2026Review
- Physiological biodistribution ofFrontiers in nuclear medicine · 2026Article
- Article
- Evaluation of a digital bismuth germanium oxide PET/CT system according to the Japanese brain tumor phantom test forPhysical and engineering sciences in medicine · 2025Article
- Potential impact of [Radiation oncology (London, England) · 2025Article
- Study of 18 F-fluciclovine PET for serial assessment of glioblastoma tumor volumes during surgery and radiotherapy.Journal of neuro-oncology · 2025Article
- Identification of small distant glioblastoma lesions using 18F-fluciclovine positron emission tomography: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Utility of [18F]fluciclovine PET/MRI for identifying the optimal biopsy target region, helping to avoid underdiagnosis in patients with glioblastoma: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment.International journal of molecular sciences · 2025Review
- Phantom test procedures for a new neuro-oncological amino acid PET tracer: [Annals of nuclear medicine · 2025Article
- Intraoperative glioblastoma surgery-current challenges and clinical trials: An update.Cancer pathogenesis and therapy · 2024Review
- Histomolecular Validation of [Cancers · 2024Article
- Impact of [Annals of nuclear medicine · 2024Article
- Article
- Diagnostic accuracy of anti-3-[European journal of nuclear medicine and molecular imaging · 2024Article
- Diagnostic Accuracy of PET withDiagnostics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectives
methodsSix consecutive patients (four male, two female), who were clinically suspected of having high- or low-grade glioma, received both FACBC-PET and MET-PET within a two-week interval. T1-weighted, contrast-enhanced, T1-weighted, and fluid-attenuated inversion recovery magnetic resonance imaging was performed to assist with subsequent tissue resection. Visual findings and semi-quantitative analyses of FACBC and MET uptake, using standardized uptake values (SUVs) and lesion-to-contralateral normal brain tissue (LN) ratios, were evaluated to compare PET images.
resultsSUVs for FACBC were lower than those for MET in the non-lesion cerebral cortex, brain stem, and cerebellar hemisphere. There was a weak positive correlation between FACBC and MET uptake in glioma tissue, although L/N ratios for FACBC were higher than those for MET in all the cases.
conclusionFACBC-PET showed higher contrast than MET-PET by both visual and semi-quantitative analyses and may therefore provide better assessment for the detection of glioma. This study was registered as clinical trial (No. JapicCTI-132289).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.